249 related articles for article (PubMed ID: 20500904)
1. Activation of HER family members in gastric carcinoma cells mediates resistance to MET inhibition.
Corso S; Ghiso E; Cepero V; Sierra JR; Migliore C; Bertotti A; Trusolino L; Comoglio PM; Giordano S
Mol Cancer; 2010 May; 9():121. PubMed ID: 20500904
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts.
Ji F; Liu X; Wu Y; Fang X; Huang G
Drug Des Devel Ther; 2015; 9():5697-704. PubMed ID: 26543351
[TBL] [Abstract][Full Text] [Related]
3. MET activation mediates resistance to lapatinib inhibition of HER2-amplified gastric cancer cells.
Chen CT; Kim H; Liska D; Gao S; Christensen JG; Weiser MR
Mol Cancer Ther; 2012 Mar; 11(3):660-9. PubMed ID: 22238368
[TBL] [Abstract][Full Text] [Related]
4. HER kinase activation confers resistance to MET tyrosine kinase inhibition in MET oncogene-addicted gastric cancer cells.
Bachleitner-Hofmann T; Sun MY; Chen CT; Tang L; Song L; Zeng Z; Shah M; Christensen JG; Rosen N; Solit DB; Weiser MR
Mol Cancer Ther; 2008 Nov; 7(11):3499-508. PubMed ID: 18974395
[TBL] [Abstract][Full Text] [Related]
5. Multiple mutations and bypass mechanisms can contribute to development of acquired resistance to MET inhibitors.
Qi J; McTigue MA; Rogers A; Lifshits E; Christensen JG; Jänne PA; Engelman JA
Cancer Res; 2011 Feb; 71(3):1081-91. PubMed ID: 21266357
[TBL] [Abstract][Full Text] [Related]
6. Identification of short-form RON as a novel intrinsic resistance mechanism for anti-MET therapy in MET-positive gastric cancer.
Wu Z; Zhang Z; Ge X; Lin Y; Dai C; Chang J; Liu X; Geng R; Wang C; Chen H; Sun M; Guo W; Li J
Oncotarget; 2015 Dec; 6(38):40519-34. PubMed ID: 26528757
[TBL] [Abstract][Full Text] [Related]
7. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma.
Catenacci DV; Cervantes G; Yala S; Nelson EA; El-Hashani E; Kanteti R; El Dinali M; Hasina R; Brägelmann J; Seiwert T; Sanicola M; Henderson L; Grushko TA; Olopade O; Karrison T; Bang YJ; Kim WH; Tretiakova M; Vokes E; Frank DA; Kindler HL; Huet H; Salgia R
Cancer Biol Ther; 2011 Jul; 12(1):9-46. PubMed ID: 21543897
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of Src impairs the growth of met-addicted gastric tumors.
Bertotti A; Bracco C; Girolami F; Torti D; Gastaldi S; Galimi F; Medico E; Elvin P; Comoglio PM; Trusolino L
Clin Cancer Res; 2010 Aug; 16(15):3933-43. PubMed ID: 20628031
[TBL] [Abstract][Full Text] [Related]
9. Truncated RAF kinases drive resistance to MET inhibition in MET-addicted cancer cells.
Petti C; Picco G; Martelli ML; Trisolini E; Bucci E; Perera T; Isella C; Medico E
Oncotarget; 2015 Jan; 6(1):221-33. PubMed ID: 25473895
[TBL] [Abstract][Full Text] [Related]
10. MET and KRAS gene amplification mediates acquired resistance to MET tyrosine kinase inhibitors.
Cepero V; Sierra JR; Corso S; Ghiso E; Casorzo L; Perera T; Comoglio PM; Giordano S
Cancer Res; 2010 Oct; 70(19):7580-90. PubMed ID: 20841479
[TBL] [Abstract][Full Text] [Related]
11. Heat-shock protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibitors and confers resistance to MET-targeted therapy.
Musiani D; Konda JD; Pavan S; Torchiaro E; Sassi F; Noghero A; Erriquez J; Perera T; Olivero M; Di Renzo MF
FASEB J; 2014 Sep; 28(9):4055-67. PubMed ID: 24903273
[TBL] [Abstract][Full Text] [Related]
12. Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition.
Okamoto W; Okamoto I; Yoshida T; Okamoto K; Takezawa K; Hatashita E; Yamada Y; Kuwata K; Arao T; Yanagihara K; Fukuoka M; Nishio K; Nakagawa K
Mol Cancer Ther; 2010 May; 9(5):1188-97. PubMed ID: 20406949
[TBL] [Abstract][Full Text] [Related]
13. Establishment of patient-derived gastric cancer xenografts: a useful tool for preclinical evaluation of targeted therapies involving alterations in HER-2, MET and FGFR2 signaling pathways.
Wang H; Lu J; Tang J; Chen S; He K; Jiang X; Jiang W; Teng L
BMC Cancer; 2017 Mar; 17(1):191. PubMed ID: 28292264
[TBL] [Abstract][Full Text] [Related]
14. Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.
Yamaoka T; Ohmori T; Ohba M; Arata S; Kishino Y; Murata Y; Kusumoto S; Ishida H; Shirai T; Hirose T; Ohnishi T; Sasaki Y
Mol Cancer Ther; 2016 Dec; 15(12):3040-3054. PubMed ID: 27612490
[TBL] [Abstract][Full Text] [Related]
15. Acquired resistance mechanisms to afatinib in HER2-amplified gastric cancer cells.
Yoshioka T; Shien K; Takeda T; Takahashi Y; Kurihara E; Ogoshi Y; Namba K; Torigoe H; Sato H; Tomida S; Yamamoto H; Soh J; Fujiwara T; Toyooka S
Cancer Sci; 2019 Aug; 110(8):2549-2557. PubMed ID: 31162771
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of SNX-2112, a synthetic heat shock protein-90 inhibitor, in MET-amplified tumor cells with or without resistance to selective MET Inhibition.
Bachleitner-Hofmann T; Sun MY; Chen CT; Liska D; Zeng Z; Viale A; Olshen AB; Mittlboeck M; Christensen JG; Rosen N; Solit DB; Weiser MR
Clin Cancer Res; 2011 Jan; 17(1):122-33. PubMed ID: 21208906
[TBL] [Abstract][Full Text] [Related]
17. Coactivation of receptor tyrosine kinases in malignant mesothelioma as a rationale for combination targeted therapy.
Brevet M; Shimizu S; Bott MJ; Shukla N; Zhou Q; Olshen AB; Rusch V; Ladanyi M
J Thorac Oncol; 2011 May; 6(5):864-74. PubMed ID: 21774103
[TBL] [Abstract][Full Text] [Related]
18. MET expression and amplification in patients with localized gastric cancer.
Janjigian YY; Tang LH; Coit DG; Kelsen DP; Francone TD; Weiser MR; Jhanwar SC; Shah MA
Cancer Epidemiol Biomarkers Prev; 2011 May; 20(5):1021-7. PubMed ID: 21393565
[TBL] [Abstract][Full Text] [Related]
19. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
20. Ron kinase transphosphorylation sustains MET oncogene addiction.
Benvenuti S; Lazzari L; Arnesano A; Li Chiavi G; Gentile A; Comoglio PM
Cancer Res; 2011 Mar; 71(5):1945-55. PubMed ID: 21212418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]